HRP990049A2 - Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors - Google Patents
Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors Download PDFInfo
- Publication number
- HRP990049A2 HRP990049A2 HR60/074,881A HRP990049A HRP990049A2 HR P990049 A2 HRP990049 A2 HR P990049A2 HR P990049 A HRP990049 A HR P990049A HR P990049 A2 HRP990049 A2 HR P990049A2
- Authority
- HR
- Croatia
- Prior art keywords
- reverse transcriptase
- benzoxazinone
- mixture according
- hiv reverse
- fatty acids
- Prior art date
Links
- HQQTZCPKNZVLFF-UHFFFAOYSA-N 4h-1,2-benzoxazin-3-one Chemical class C1=CC=C2ONC(=O)CC2=C1 HQQTZCPKNZVLFF-UHFFFAOYSA-N 0.000 title claims description 14
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 title claims description 9
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 title description 4
- 239000012669 liquid formulation Substances 0.000 title description 2
- 239000000203 mixture Substances 0.000 claims description 46
- 239000003765 sweetening agent Substances 0.000 claims description 14
- -1 polyol esters Chemical class 0.000 claims description 13
- 235000003599 food sweetener Nutrition 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 10
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 9
- XPOQHMRABVBWPR-ZDUSSCGKSA-N efavirenz Chemical compound C([C@]1(C2=CC(Cl)=CC=C2NC(=O)O1)C(F)(F)F)#CC1CC1 XPOQHMRABVBWPR-ZDUSSCGKSA-N 0.000 claims description 9
- 150000003626 triacylglycerols Chemical class 0.000 claims description 9
- 229930006000 Sucrose Natural products 0.000 claims description 8
- 239000005720 sucrose Substances 0.000 claims description 8
- 230000002401 inhibitory effect Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 150000004667 medium chain fatty acids Chemical class 0.000 claims description 6
- 229920005862 polyol Polymers 0.000 claims description 6
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 5
- 239000007903 gelatin capsule Substances 0.000 claims description 5
- 239000000787 lecithin Substances 0.000 claims description 5
- 235000010445 lecithin Nutrition 0.000 claims description 5
- 229940067606 lecithin Drugs 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 4
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 claims description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 claims description 3
- 150000004665 fatty acids Chemical class 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 description 11
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000009472 formulation Methods 0.000 description 7
- XPOQHMRABVBWPR-UHFFFAOYSA-N Efavirenz Natural products O1C(=O)NC2=CC=C(Cl)C=C2C1(C(F)(F)F)C#CC1CC1 XPOQHMRABVBWPR-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000008186 active pharmaceutical agent Substances 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 229940088679 drug related substance Drugs 0.000 description 6
- 229960003804 efavirenz Drugs 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000000049 pigment Substances 0.000 description 5
- 239000005711 Benzoic acid Substances 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 235000010233 benzoic acid Nutrition 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 208000030507 AIDS Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 150000002711 medium chain fatty acid esters Chemical class 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 241000220223 Fragaria Species 0.000 description 2
- 235000016623 Fragaria vesca Nutrition 0.000 description 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- LIKBJVNGSGBSGK-UHFFFAOYSA-N iron(3+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Fe+3].[Fe+3] LIKBJVNGSGBSGK-UHFFFAOYSA-N 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000021092 sugar substitutes Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- STORWMDPIHOSMF-UHFFFAOYSA-N decanoic acid;octanoic acid;propane-1,2,3-triol Chemical compound OCC(O)CO.CCCCCCCC(O)=O.CCCCCCCCCC(O)=O STORWMDPIHOSMF-UHFFFAOYSA-N 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 239000003168 generic drug Substances 0.000 description 1
- 239000007970 homogeneous dispersion Substances 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 229960005015 local anesthetics Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000007971 pharmaceutical suspension Substances 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7488198P | 1998-02-17 | 1998-02-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP990049A2 true HRP990049A2 (en) | 1999-12-31 |
Family
ID=22122226
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR60/074,881A HRP990049A2 (en) | 1998-02-17 | 1999-02-17 | Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6235733B1 (es) |
| EP (1) | EP1054674B1 (es) |
| JP (1) | JP2002502878A (es) |
| CN (1) | CN1170541C (es) |
| AR (1) | AR018092A1 (es) |
| AT (1) | ATE345802T1 (es) |
| AU (1) | AU745008C (es) |
| BR (2) | BRPI9908132B8 (es) |
| CA (1) | CA2319609C (es) |
| DE (1) | DE69934097T2 (es) |
| ES (1) | ES2277429T3 (es) |
| HK (1) | HK1030749A1 (es) |
| HR (1) | HRP990049A2 (es) |
| IL (1) | IL137763A0 (es) |
| MY (1) | MY139034A (es) |
| NZ (1) | NZ506579A (es) |
| TW (1) | TW528596B (es) |
| WO (1) | WO1999040921A2 (es) |
| ZA (1) | ZA99981B (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3525792A4 (en) * | 2016-10-11 | 2020-04-22 | Aucta Pharmaceuticals | POWDER FOR ORAL SUSPENSION CONTAINING LAMOTRIGIN |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI111730B (fi) * | 1990-11-02 | 2003-09-15 | Novartis Ag | Menetelmä ei-immunosuppressiivisen syklosporiinin valmistamiseksi |
| US5494936A (en) * | 1992-04-27 | 1996-02-27 | Vyrex Corporation | Delivery formulation for probucol |
| US5665720A (en) | 1992-08-07 | 1997-09-09 | Merck & Co., Inc. | Benzoxazinones as inhibitors of HIV reverse transcriptase |
| WO1995020389A1 (en) | 1994-01-28 | 1995-08-03 | Merck & Co., Inc. | Benzoxazinones as inhibitors of hiv reverse transcriptase |
| AU712120B2 (en) | 1996-05-02 | 1999-10-28 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| CA2268953A1 (en) * | 1996-10-02 | 1998-04-09 | Du Pont Pharmaceuticals Company | 4,4-disubstituted-1,4-dihydro-2h-3,1-benzoxazin-2-ones useful as hiv reverse transcriptase inhibitors and intermediates and processes for making the same |
-
1999
- 1999-02-08 ZA ZA9900981A patent/ZA99981B/xx unknown
- 1999-02-13 MY MYPI99000529A patent/MY139034A/en unknown
- 1999-02-16 AR ARP990100630A patent/AR018092A1/es active IP Right Grant
- 1999-02-16 US US09/250,508 patent/US6235733B1/en not_active Expired - Lifetime
- 1999-02-17 AT AT99907077T patent/ATE345802T1/de active
- 1999-02-17 CA CA002319609A patent/CA2319609C/en not_active Expired - Lifetime
- 1999-02-17 BR BRPI9908132A patent/BRPI9908132B8/pt not_active IP Right Cessation
- 1999-02-17 IL IL13776399A patent/IL137763A0/xx not_active IP Right Cessation
- 1999-02-17 AU AU26827/99A patent/AU745008C/en not_active Expired
- 1999-02-17 EP EP99907077A patent/EP1054674B1/en not_active Expired - Lifetime
- 1999-02-17 BR BRPI9908132A patent/BRPI9908132C1/pt unknown
- 1999-02-17 NZ NZ506579A patent/NZ506579A/xx not_active IP Right Cessation
- 1999-02-17 DE DE69934097T patent/DE69934097T2/de not_active Expired - Lifetime
- 1999-02-17 CN CNB998029505A patent/CN1170541C/zh not_active Expired - Lifetime
- 1999-02-17 HR HR60/074,881A patent/HRP990049A2/hr not_active Application Discontinuation
- 1999-02-17 JP JP2000531173A patent/JP2002502878A/ja active Pending
- 1999-02-17 ES ES99907077T patent/ES2277429T3/es not_active Expired - Lifetime
- 1999-02-17 WO PCT/US1999/003318 patent/WO1999040921A2/en active IP Right Grant
- 1999-02-23 TW TW088102274A patent/TW528596B/zh not_active IP Right Cessation
-
2001
- 2001-03-08 HK HK01101680A patent/HK1030749A1/xx not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| MY139034A (en) | 2009-08-28 |
| JP2002502878A (ja) | 2002-01-29 |
| TW528596B (en) | 2003-04-21 |
| HK1030749A1 (en) | 2001-05-18 |
| EP1054674A2 (en) | 2000-11-29 |
| AU2682799A (en) | 1999-08-30 |
| IL137763A0 (en) | 2001-10-31 |
| ES2277429T3 (es) | 2007-07-01 |
| BRPI9908132C1 (pt) | 2021-05-25 |
| BR9908132A (pt) | 2000-12-05 |
| AU745008C (en) | 2003-03-27 |
| BRPI9908132B1 (pt) | 2015-07-14 |
| CN1291098A (zh) | 2001-04-11 |
| US6235733B1 (en) | 2001-05-22 |
| AR018092A1 (es) | 2001-10-31 |
| DE69934097T2 (de) | 2007-06-28 |
| DE69934097D1 (de) | 2007-01-04 |
| CN1170541C (zh) | 2004-10-13 |
| EP1054674B1 (en) | 2006-11-22 |
| ATE345802T1 (de) | 2006-12-15 |
| AU745008B2 (en) | 2002-03-07 |
| WO1999040921A3 (en) | 1999-11-04 |
| NZ506579A (en) | 2002-11-26 |
| BRPI9908132B8 (pt) | 2016-11-16 |
| CA2319609A1 (en) | 1999-08-19 |
| WO1999040921A2 (en) | 1999-08-19 |
| ZA99981B (en) | 2000-08-08 |
| CA2319609C (en) | 2007-09-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69732412T2 (de) | Bukales, polares spray | |
| US5200192A (en) | Instant oral-release capsule containing nifedipine | |
| IE883843L (en) | Granules of cimetidine useful in preparing tablets thereof | |
| CA2907195A1 (en) | Racecadotril lipid compositions | |
| ES2684491T3 (es) | Tecnología para la administración de fármacos | |
| JPH07242536A (ja) | 皮膜に精油成分が含有されたゼラチンカプセル剤 | |
| CA2319609C (en) | Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors | |
| AU2013288231B2 (en) | Pediatric oral liquid compositions containing Nepadutant | |
| ES2325373T3 (es) | Composicion farmaceutica destinada a la administracion oral de un derivado de pirazol-3-carboxamida. | |
| US20020061884A1 (en) | Oral liquid formulations of benzoxazinones HIV reverse transcriptase inhibitors | |
| EP0228223A2 (en) | Non-irritating suprofen solution | |
| US7632853B2 (en) | Soluble, stable and concentrated pharmaceutical composition compromising ritonavir and process for preparing thereof | |
| MXPA00007579A (es) | Formulaciones liquidas orales de inhibidores de la transcriptasa inversa del vih de benzoxazinonas | |
| JP2002540158A (ja) | レトロウイルスプロテアーゼインヒビター用医薬エマルジョン | |
| KR20030074822A (ko) | 약학 조성물 | |
| US20060217320A1 (en) | Soft gel formulations for saquinavir | |
| OA17358A (en) | Pediatric oral liquid compositions containing nepadutant. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| AIPI | Request for the grant of a patent on the basis of a substantive examination of a patent application | ||
| ODBC | Application rejected |